Skip to main content

Table 3 The Total Public Expenditure on OMPs in Euro per Capita in 7 EU Countries in 2013 and 2014

From: The European challenges of funding orphan medicinal products

  Austrial Belgium Bulgariam Czech Republicn Hungary Poland Slovenia
2013
 Total public expenditure on OMPs in local currency 98,600,000 €a 245,000,000 €b 16,201,220 BGNc 1,100,000,000 CZKd 9,577,605,323 HUFe 212,725,536 PLNf 16,893,308 €g
 Eurostat exchange rate - annual data (/1 €)    1.96 BGNh 25.98 CZKh 296.87 HUFh 4.20 PLNh  
 Total public expenditure on OMPs in € 98,600,000 245,000,000 8266,000 42,340,000 32,262,000 50,649,000 16,893,000
 Size of population 8,500,000j 11,161,642i 7,284,552i 10,516,125i 9,908,798i 38,062,535i 2,058,821i
 Total public expenditure on OMPs in €/capita 11.60 21.95 1.13 4.03 3.26 1.33 8.21
2014
 Total public expenditure on OMPs in local currency 109,800,000 €a 280,000,000 €b 23,967,183 BGNc 1,400,000,000 CZKo 12,501,994,171 HUFe 348,368,792PLNf 19,853,716 €g
 Eurostat exchange rate - annual data (/1 €)    1.96 BGNh 27.54 CZKh 308.71 HUFh 4.18 PLNh  
 Total public expenditure on OMPs in € 109,800,000 280,000,000 12,228,000 50,835,000 40,496,000 83,342,000 19,854,000
 Size of population 8,500,000k 11,180,840i 7,245,677i 10,512,419i 9,877,365i 38,017,856i i2,061,085
 Total public expenditure on OMPs in €/capita 12.92 25.04 1.69 4.84 4.10 2.19 9.63
 Average of total expenditure on OMP in €/capita in 2013 and 2014 12.26 23.50 1.41 4.43 3.68 1.76 8.92
  1. Sources: a Federation of Austrian Social Insurance Institutions (Hauptverband der österreichischen Sozialversicherungsträger)
  2. bNational Institute for Health and Disability Insurance of Belgium (Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor ziekte-en invaliditeitsverzekering, INAMI / RIZIV)
  3. cNational Health Insurance Fund of Bulgaria, National Council on Prices and Reimbursement of Medicinal Products
  4. dState Institute for Drug Control (Státní ústav pro kontrolu léčiv, SUKL)
  5. e National Health Insurance Fund Administration of Hungary (Országos Egészségbiztosítási Pénztár, OEP)
  6. fNational Health Fund (Narodowy Fundusz Zdrowia), Ministry of Health (Ministerstwo Zdrowia)
  7. g Health Insurance Institute of Slovenia (Zavod za zdravstveno zavarovanje Slovenije, ZZZS)
  8. h http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=ert_bil_eur_a&lang=en
  9. ihttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_gind&lang=en
  10. jAustrian data was not available on Eurostat database, the source: https://data.oecd.org/pop/population.htm
  11. kAustrian data was not available on Eurostat or OECD database, the calculated number was taken from the previous year
  12. lOrphan drug expenditure in hospitals not included
  13. mThese data was based on 10 OMs reimbursed by National Health Insurance Fund
  14. nAdditional drugs were identified which held orphan designation until 2013/14 with significant costs (Glivec, Ilaris, Ventavis)
  15. oData was not available at time of data request; this number assumes same total expenditure on public healthcare as in year 2013